Colorectal Cancer Drugs Global Market Report 2025

Description

Colorectal cancer (CRC) or bowel cancer is a form of cancer that affects the large intestine and the rectum. Depending on their origin, these cancers are referred to as either colon tumors or rectal cancer.

The main types of drugs used for colorectal cancer treatment include vascular endothelial growth factor (VEGF) inhibitors, epidermal growth factor receptor (EGFR) inhibitors, programmed cell death protein 1/PD1 ligand 1 (PD1/PDL1) inhibitors, BRAF or MEK inhibitors, tyrosine kinase (TKI) inhibitors, and immunomodulators. Vascular endothelial growth factor (VEGF) inhibitors are drugs that block VEGF and VEGFR activity. The different classes of drugs include immunotherapy, chemotherapy, and others, and these medications are typically dispensed through hospital pharmacies, retail pharmacies, and other distribution channels.

The colorectal cancer drugs market research report is one of a series of new reports from The Business Research Company that provides colorectal cancer drugs market statistics, including colorectal cancer drugs industry global market size, regional shares, competitors with a colorectal cancer drugs market share, detailed colorectal cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the colorectal cancer drugs industry. This colorectal cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The colorectal cancer drugs market size has grown strongly in recent years. It will grow from $20.71 billion in 2024 to $21.98 billion in 2025 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to integration of multimodal approaches, introduction of chemotherapy, advancements in surgical techniques, emergence of targeted therapies, clinical trials and research.

The colorectal cancer drugs market size is expected to see strong growth in the next few years. It will grow to $27.53 billion in 2029 at a compound annual growth rate (CAGR) of 5.8%. The growth in the forecast period can be attributed to rise in personalized treatment, patient-centric care models, expansion of targeted therapies, adoption of combination therapies, regulatory acceleration. Major trends in the forecast period include immunotherapy advancements, precision medicine evolution, combination therapies, biomarker research and use, clinical trials innovation.

The rising demand for personalized medicines is expected to drive the growth of the colorectal cancer drugs market in the future. Personalized medicine, also known as precision medicine, is an approach to medical treatment and healthcare that considers individual differences in patients' genes, environments, and lifestyles. This approach is revolutionizing the treatment of colorectal cancer (CRC), providing more individualized and effective care for patients. As research and drug development become increasingly tailored to specific genetic and molecular profiles, it is likely to continue propelling the growth of the CRC drug market. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA approved 16 new personalized therapies for patients with rare diseases in 2023, a significant rise from the six approved in 2022. Therefore, the growing demand for personalized medicine is driving the expansion of the colorectal cancer drugs market.

The colorectal cancer drugs market is also expected to witness growth due to the escalating number of clinical trials. Clinical trials, involving human volunteers, evaluate the safety and efficacy of various medical treatments, including drugs designed for colorectal cancer treatment. These trials play a crucial role in identifying novel therapies that can enhance patient outcomes, potentially introducing new drugs to the market. The substantial increase in the number of clinical trials, with over 452,000 registered studies and more than 64,000 actively seeking participants, as reported by Xtalks in May 2023, indicates a significant rise compared to early 2021. This surge in clinical trials is contributing to the growth of the colorectal cancer drugs market.

Major companies in the colorectal cancer drugs market are focused on gaining FDA approvals for new drugs to enhance profitability. An example is LONSURF (trifluridine/tipiracil), an oral prescription medication approved by the FDA for treating specific cancers such as colon, rectal, and stomach cancer that has metastasized. Taiho Pharmaceutical Co. Ltd. announced FDA approval for LONSURF in combination with bevacizumab for treating metastatic colorectal cancer in August 2023. The combination significantly increased overall and progression-free survival compared to LONSURF alone.

In October 2023, the Bristol-Myers Squibb Company acquired Mirati Therapeutics Inc for $5.8 billion. This strategic move aimed to add KRAZATI, a prominent lung cancer drug, to Bristol Myers Squibb's commercial portfolio, enhancing and diversifying its oncology offerings. The acquisition aligns with Bristol-Myers Squibb's mission to uncover scientific advancements that promise a life free from cancer. Mirati Therapeutics Inc., a US-based biotech company, contributes valuable therapies to Bristol-Myers Squibb's efforts in the field of oncology.

Major companies operating in the colorectal cancer drugs market include Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Amgen Inc., Astellas Pharma Inc., Servier Laboratories, Eisai Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Ipsen SA, Taiho Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Taiho Oncology Inc., Ono Pharmaceutical Co. Ltd., Daiichi Sankyo Company Limited, Otsuka Pharmaceutical Co. Ltd., Mundipharma International Limited, Teva Pharmaceutical Industries Ltd., Gilead Sciences Inc., Johnson & Johnson Services Inc., Spectrum Pharmaceuticals Inc., Exelixis Inc., Seattle Genetics Inc., Incyte Corporation, Clovis Oncology Inc., Karyopharm Therapeutics Inc.

North America was the largest region in the colorectal cancer drugs market in 2024. The Middle East is expected to be the fastest-growing region in the global colorectal cancer drugs market share during the forecast period. The regions covered in the colorectal cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the colorectal cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The colorectal cancer drugs market consists of sales of avastin, bevacizumab, and camptosar. Values in the colorectal cancer drugs market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Colorectal Cancer Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on colorectal cancer drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for colorectal cancer drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The colorectal cancer drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type: Vascular Endothelial Growth Factor (VEGF) Inhibitors; Epidermal Growth Factor Receptor (EGFR) Inhibitors; Programmed Cell Death Protein 1 Or PD1 Ligand 1 (PD1 Or PDL1) Inhibitors; BRAF Or MEK Inhibitors; Tyrosine Kinase (TKI) Inhibitors; Immunomodulators
2) By Class: Immunotherapy; Chemotherapy; Other Classes
3) By Distribution Channels: Hospitals Pharmacies; Retail Pharmacies; Other Distribution Channels
Subsegments:
1) By Vascular Endothelial Growth Factor (VEGF) Inhibitors: Bevacizumab; Ramucirumab; Other VEGF Inhibitors
2) By Epidermal Growth Factor Receptor (EGFR) Inhibitors: Cetuximab; Panitumumab; Other EGFR Inhibitors
3) By Programmed Cell Death Protein 1 Or PD1 Ligand 1 (PD1 Or PDL1) Inhibitors: Pembrolizumab; Nivolumab; Other PD1 Or PDL1 Inhibitors
4) By BRAF Or MEK Inhibitors: Vemurafenib; Encorafenib; Trametinib; Other BRAF Or MEK Inhibitors
5) By Tyrosine Kinase (TKI) Inhibitors: Regorafenib; Sorafenib; Other TKI Inhibitors
6) By Immunomodulators: Checkpoint Inhibitors; Other Immunomodulating Agents
Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; AbbVie Inc.; Bayer AG; Novartis AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r26257

1. Executive Summary

2. Colorectal Cancer Drugs Market Characteristics

3. Colorectal Cancer Drugs Market Trends And Strategies

4. Colorectal Cancer Drugs Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Colorectal Cancer Drugs Growth Analysis And Strategic Analysis Framework

5.1. Global Colorectal Cancer Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Colorectal Cancer Drugs Market Growth Rate Analysis
5.4. Global Colorectal Cancer Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Colorectal Cancer Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Colorectal Cancer Drugs Total Addressable Market (TAM)

6. Colorectal Cancer Drugs Market Segmentation

6.1. Global Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Vascular Endothelial Growth Factor (VEGF) Inhibitors
Epidermal Growth Factor Receptor (EGFR) Inhibitors
Programmed Cell Death Protein 1 Or PD1 Ligand 1 (PD1 Or PDL1) Inhibitors
BRAF Or MEK Inhibitors
Tyrosine Kinase (TKI) Inhibitors
Immunomodulators
6.2. Global Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Immunotherapy
Chemotherapy
Other Classes
6.3. Global Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals Pharmacies
Retail Pharmacies
Other Distribution Channels
6.4. Global Colorectal Cancer Drugs Market, Sub-Segmentation Of Vascular Endothelial Growth Factor (VEGF) Inhibitorsm, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Bevacizumab
Ramucirumab
Other VEGF Inhibitors
6.5. Global Colorectal Cancer Drugs Market, Sub-Segmentation Of Epidermal Growth Factor Receptor (EGFR) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Cetuximab
Panitumumab
Other EGFR Inhibitors
6.6. Global Colorectal Cancer Drugs Market, Sub-Segmentation Of Programmed Cell Death Protein 1 Or PD1 Ligand 1 (PD1 Or PDL1) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pembrolizumab
Nivolumab
Other PD1 Or PDL1 Inhibitors
6.7. Global Colorectal Cancer Drugs Market, Sub-Segmentation Of BRAF Or MEK Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Vemurafenib
Encorafenib
Trametinib
6.8. Global Colorectal Cancer Drugs Market, Sub-Segmentation Of Tyrosine Kinase (TKI) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Regorafenib
Sorafenib
Other TKI Inhibitors
6.9. Global Colorectal Cancer Drugs Market, Sub-Segmentation Of Immunomodulators, By type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Checkpoint Inhibitors
Other Immunomodulating Agents

7. Colorectal Cancer Drugs Market Regional And Country Analysis

7.1. Global Colorectal Cancer Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Colorectal Cancer Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Colorectal Cancer Drugs Market

8.1. Asia-Pacific Colorectal Cancer Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Colorectal Cancer Drugs Market

9.1. China Colorectal Cancer Drugs Market Overview
9.2. China Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Colorectal Cancer Drugs Market

10.1. India Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Colorectal Cancer Drugs Market

11.1. Japan Colorectal Cancer Drugs Market Overview
11.2. Japan Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Colorectal Cancer Drugs Market

12.1. Australia Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Colorectal Cancer Drugs Market

13.1. Indonesia Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Colorectal Cancer Drugs Market

14.1. South Korea Colorectal Cancer Drugs Market Overview
14.2. South Korea Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Colorectal Cancer Drugs Market

15.1. Western Europe Colorectal Cancer Drugs Market Overview
15.2. Western Europe Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Colorectal Cancer Drugs Market

16.1. UK Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Colorectal Cancer Drugs Market

17.1. Germany Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Colorectal Cancer Drugs Market

18.1. France Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Colorectal Cancer Drugs Market

19.1. Italy Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Colorectal Cancer Drugs Market

20.1. Spain Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Colorectal Cancer Drugs Market

21.1. Eastern Europe Colorectal Cancer Drugs Market Overview
21.2. Eastern Europe Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Colorectal Cancer Drugs Market

22.1. Russia Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Colorectal Cancer Drugs Market

23.1. North America Colorectal Cancer Drugs Market Overview
23.2. North America Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Colorectal Cancer Drugs Market

24.1. USA Colorectal Cancer Drugs Market Overview
24.2. USA Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Colorectal Cancer Drugs Market

25.1. Canada Colorectal Cancer Drugs Market Overview
25.2. Canada Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Colorectal Cancer Drugs Market

26.1. South America Colorectal Cancer Drugs Market Overview
26.2. South America Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Colorectal Cancer Drugs Market

27.1. Brazil Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Colorectal Cancer Drugs Market

28.1. Middle East Colorectal Cancer Drugs Market Overview
28.2. Middle East Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Colorectal Cancer Drugs Market

29.1. Africa Colorectal Cancer Drugs Market Overview
29.2. Africa Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Colorectal Cancer Drugs Market Competitive Landscape And Company Profiles

30.1. Colorectal Cancer Drugs Market Competitive Landscape
30.2. Colorectal Cancer Drugs Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Colorectal Cancer Drugs Market Other Major And Innovative Companies

31.1. Sanofi SA
31.2. Bristol-Myers Squibb Company
31.3. AstraZeneca plc
31.4. Takeda Pharmaceutical Company Limited
31.5. F. Hoffmann-La Roche Ltd.
31.6. Eli Lilly and Company
31.7. Amgen Inc.
31.8. Astellas Pharma Inc.
31.9. Servier Laboratories
31.10. Eisai Co. Ltd.
31.11. Sumitomo Dainippon Pharma Co. Ltd.
31.12. Ipsen SA
31.13. Taiho Pharmaceutical Co. Ltd.
31.14. Kyowa Kirin Co. Ltd.
31.15. Taiho Oncology Inc.

32. Global Colorectal Cancer Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Colorectal Cancer Drugs Market

34. Recent Developments In The Colorectal Cancer Drugs Market

35. Colorectal Cancer Drugs Market High Potential Countries, Segments and Strategies

35.1 Colorectal Cancer Drugs Market In 2029 - Countries Offering Most New Opportunities
35.2 Colorectal Cancer Drugs Market In 2029 - Segments Offering Most New Opportunities
35.3 Colorectal Cancer Drugs Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer